A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Gene</td><td class="align_center">Primers</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left" rowspan="2"><i>β</i>-Actin</td><td class="align_center">F: CACCATTGGCAATGAGCGGTTC</td></tr><tr><td class="align_center">R: AGGTCTTTGCGGATGTCCACGT</td></tr><tr><td class="align_left" rowspan="2">EPO</td><td class="align_center">F: ATGTGGATAAAGCCGTCAGTG</td></tr><tr><td class="align_center">R: AAAGTGTCAGCAGTGATTGTTC</td></tr><tr><td class="align_left" rowspan="2">HMOX1</td><td class="align_center">F: CCTCCCTGTACCACATCTATGT</td></tr><tr><td class="align_center">R: GCTCTTCTGGGAAGTAGACAG</td></tr><tr><td class="align_left" rowspan="2">SERPINE1</td><td class="align_center">F: AACGTGGTTTTCTCACCCTAT</td></tr><tr><td class="align_center">R: CAATCTTGAATCCCATAGCTGC</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Journal of Oncology

tab1

Table 1

Table 1: A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 

Table 1 | A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 